Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study

HOPKINTON, Mass., Oct. 13 /PRNewswire/ -- Facet Solutions, Inc. today announced the completion of 6 month follow-up on 20 patients from its US IDE Pilot Study. The results show a 78% reduction in Oswestry Disability Index (ODI) scores, and an 80% reduction in Visual Analog Scores (VAS) for sym...

Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period

Results of FLEXX Trial Presented at the Osteoarthritis Research Society International's 2008 World Congress PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc. recently presented results from the FLEXX Trial of Osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium...

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attri...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

Results show promising neurological recovery in severely-injured, acute cervical spinal cord injury patients treated with Cethrin HOPKINTON, Mass., May 12 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE ) today announced 12-month interim data from its Phase I/IIa c...

Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced the release to television news stations nationwide of an independently produced video report featuring metastatic melanoma patients treated with the company's Allovectin-7(R) immunotherapeutic pro...

September is National Pain Awareness Month

SEVERE CHRONIC PAIN - ONE OF COUNTRY'S GREAT HIDDEN HEALTH CRISES - 70 MILLION AMERICANS SUFFER WITHOUT RELIEF Treatment Developed from Sea Snail Offers Relief for Severe Chronic Pain Sufferers NEW YORK, Sept. 28 /PRNewswire/ -- The under-treatme...

Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month

- Presentations and panel discussions to highlight the growing local public health threat of addiction, hope offered by effective medical treatments - LIVONIA, Mich., Sept. 12 /PRNewswire/-- To mark September as National Alcohol and Drug Recovery Month, local Detroit-area community leaders are ...

September is Leukemia, Lymphoma and Myeloma Awareness Month

Tremendous advances have been made to treat blood cancer but the battle is far from won WHITE PLAINS, N.Y., Sept. 12 /PRNewswire/ -- Remarkable progress has been made in treating patients with blood cancers. Sixty years ago there were few effective treatments for ch...

Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company'...

UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age

UCB Announces Positive Top-Line Phase III Results for Keppra® as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age BRUSSELS, Belgium - April 20, 2007 - UCB today announced positive top-line results from a phase III, double-blin...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ily due to an increase in revenue from the Company's collaboration with Genzyme because the three and six months ended June 30, 2008 only included one month of amortization of the $175 million license fee that Isis received in June 2008. Isis' satellite companies also contributed to the increase i...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...first half of 2009 is approximately $27.4 million of investment in Nektar preclinical and clinical development programs. Revenue for the three month period ended June 30, 2009 was $13.0 million compared to revenue of $20.4 million in the second quarter of 2008. Revenue for the first half of 2009 w...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...te treatment with two injections administered in the deltoid muscle one week apart (Day 1 at 234 mg and Day 8 at 156 mg), followed by injections every month thereafter administered in either the deltoid or gluteal muscle. INVEGA(R) SUSTENNA(TM) was developed utilizing Elan Drug Technologies' proprietary ...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...gists in China, and look forward to their continued progress," stated Jeffrey B. Davis, Access' President and CEO. "Additionally, we are meeting this month with JCOM and key opinion leaders in Korea, and hope to get the combination trials started in Korea as soon as reasonably possible." Access int...

Treatment Shows Excellent Results for Providence Tarzana Patients Following Cardiac Arrest

...est patients are cooled to 92 degrees, is being studied nationwide to help prevent brain damage caused by a loss of blood supply. Its initial use this month in the Providence Tarzana Emergency Department and intensive care units has been 100 percent successful. "With the institution of the protocol,...

Correction to Earlier Release From Jewish Hospital and University of Louisville

... multipotent, which are the fundamental properties of stem cells." This is a small, but distinct difference than the procedure performed last month in California. We regret any misunderstanding or confusion. ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...R788 and placebo were significantly different) and month 3 (when such reported response rates were no longe...Ki3 Mean Change from Baseline in RAMRIS* Scores at month 3 Placebo 100 mg bid ... ------ ------ month 3 126/77 ...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

... WISCONSIN RAPIDS, Wis., July 23 /PRNewswire/ -- Earlier this month the University of Wisconsin Cancer Center Riverview became the first medical facility in the world to treat patients with a breakthrough treatment of ...

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

...n graft and the aorta, the main artery in the human body, during coronary artery bypass grafting (CABG) procedures. "The data published this month confirm that the PAS-Port system produces comparable patency, saves approximately five minutes per connection and eliminates the need to clamp the aor...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

...howed no evidence for benefit in the studied population. The results do not support the routine use of DHA for people with Alzheimer's. A six month study was conducted by Martek Biosciences Corporation in healthy older people to see DHA's effect on "age related cognitive decline." This trial showe...

Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline

...Karin Yurko-Mauro, PhD, Associate Director of Clinical Research at Martek, conducted a randomized, double-blind, placebo-controlled, multi-center, six month study to determine the effects of 900 mg per day of algal DHA on improving cognitive functions in 485 healthy older people (average age=70) with mild ...

Shoulder Surgery Doesn't Prevent Return to Sports

...s 68.5 with an age range from 47-93. Patients were followed for a minimum of one year. Researchers noted that activity modification until the six month point in the rehabilitation protected the shoulder against any consequence of sport, such as a deceleration injury when a golf club hits the ground or...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...d out of the study for any reason, or for whom month 6 data were unavailable, was considered a treatmen... 125/76 125/77 125/77 At month 6 123/76 125/77 125/78 Change from Baseline to month 6 (LOCF) -1.8/+0.4 +0.2/+...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

...r the metabolism of chemotherapy drugs or that make cancers more resistant or more aggressive," she adds. Hershman published a smaller study last month that found that, at least with breast cancer, disparities in survival based on race persist even after adjusting for differences in treatment. That s...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

...cription share data. This information is an estimate derived from the use of information under license from IMS National Prescription Data for the 12 month period ending December 2008. IMS expressly reserves all rights, including rights of copying, distribution and republication. ** IMS national pre...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

...ised, placebo-controlled, multi-centre trials involving 1,192 patients from 23 countries. Patients had a history of at least four partial seizures per month despite treatment with up to three concomitant anti-epileptic drugs. During the trials, patients were randomised to various dosages of ESL or p...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...ere, active ankylosing spondylitis (AS). Upon Commission approval in the European Union, SIMPONI given as a 50 mg subcutaneous injection once a month will be indicated for: In combination with methotrexate, the treatment of moderate-to-severe, active RA in adult patients when the re...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...n of morphine sulfate surrounding an inner core of naltrexone hydrochloride. EMBEDA(TM) is intended to treat moderate to severe chronic pain. This 12 month open-label safety study evaluated the plasma concentrations of naltrexone following use of ALO-01 (morphine sulfate and naltrexone hydrochloride). Sa...

Spherix Announces Positive Phase 2 Study Results

...ge serum triglycerides of the patients by -59 mg/dl by the end of the first month on therapy, a decrease from baseline that remained at -41 mg/dl by the end ...se also decreased serum LDL by an average -13 mg/dl by the end of the first month on therapy, while serum HDL was essentially unchanged (+0.9 mg/dl). The LDL...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

...w Drug Application (the "NDA") with the FDA for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is a...

Scottsdale Facility to Be First in U.S. to Showcase True REST Technology

... improvement, reported the International Journal of Stress Management. True REST sessions are priced on either a single session, monthly, twice a month or weekly rates. Group rates are available upon request. Reservations are being accepted now, with pre-opening discounts. For more information, visit ...

ThermoGenesis Announces National Institute of Health Grant

... The AXP is used for the processing of stem cells from umbilical cord blood, while the Res-Q a point-of-care device scheduled for launch later this month and the MXP are used to prepare cell concentrates from bone marrow. The Res-Q Platform is also being studied for potential use in the preparation of ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

...ly hyperglycemic animals No harmful effects such as low blood glucose levels (hypoglycemia) or detrimental changes in kidney function with 3-6 month exposure in normal or diabetic animals. "Our preclinical research during the past year on ISIS-SGLT2Rx extends previous findings ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

...ce, and in the BLOOM-DM trial, other indicators of glycemic control. In BLOSSOM and BLOOM-DM all patients will receive echocardiograms at baseline, at month 6, and at the end of the study to assess heart valve function over time. In contrast to the BLOOM trial, however, there are no echocardiographic exclu...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

...tide from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Last month Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy a...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

...S. Food and Drug Administration (the "FDA") for pixantrone to treat relapsed or refractory aggressive NHL. CTI expects to complete the submission this month and will request priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is a...

Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barrett's Esophagus

...dverse event rate was favorable, with a low stricture risk (about 1%) and no serious adverse events. After an average of 2 ablation procedures and 20 month follow-up, 77% of patients were cured of their Barrett's disease. For those patients that had baseline evidence of dysplasia, 100% had complete eradi...

Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy

...ts using a regimen of alemtuzumab pre-conditioning and tacrolimus monotherapy with subsequent weaning. Beginning at 6 months posttransplant and at 2-6 month intervals, they used a battery of clinical data including ELISA antibody titers, donor-specific antibodies and the ImmuKnow(R) assay to wean tacrolimu...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... alone. The sequential therapy of adding IC to CRT improved Time-to-Treatment Failure (TTF) from 5.0 months to 12.5 months (p< 0.0001), a 7.5 month increase. Furthermore, a secondary endpoint of loco-regional control, was observed in 61.5% of the patients treated with the sequential strategy (IC+C...